Tag

CytomX Therapeutics, Inc.

1 article

CytomX Stock Falls 46% After Overvaluation Call

InvestingPro flagged CytomX as overvalued in Jan 2026 when trading at $5.73, projecting intrinsic value $3.45 (~35% downside). By July 31, 2026 the share price dropped 45.78% to $3.10, confirming the